- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- KRAS positive
- PR positive
- PR negative
- ER negative
- BRAF positive
- PD-L1 negative
- EGFR negative
- IDH positive
- p16 positive
- CD19 positive
- HLA-A positive
- ALK negative
- ALK positive
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- MET positive
- HLA positive
- IDH negative
- TP53 positive
- ROS1 positive
- MYC positive
- MSI-H positive
- HR positive
- FLT3 positive
- p16 negative
- HLA negative
- ROS1 negative
- BRAF negative
- PALB2 positive
- NRAS positive
- HPV positive
- dMMR positive
- RB1 negative
- RB1 positive
- HLA-A negative
- NF1 positive
- PIK3CA positive
- MET negative
- RET positive
- BRCA positive
- RAS positive
- ATM positive
- BCL2 positive
- CD22 positive
- NTRK positive
- MGMT negative
- BCL6 positive
- HPV negative
- CD30 positive
- anti-dsDNA positive
- CFTR positive
- KRAS negative
- MMR positive
- ANA positive
- ARID1A positive
- BCR-ABL1 positive
- KIT positive
- NPM1 positive
- Philadelphia chromosome positive
- CCND1 positive
- MGMT positive
- MLH1 positive
- MSH6 positive
- ctDNA positive
- CD123 positive
- CHEK2 positive
- HRAS positive
- HbSS positive
- KMT2A positive
- MSH2 positive
- MTAP positive
- PD-1 positive
- PMS2 positive
- PTEN positive
- RAS negative
- CD33 positive
- FGFR2 positive
- RAD51 positive
- BRIP1 positive
- FGFR3 positive
- HBV DNA negative
- MSS positive
- NTRK1 positive
- RET negative
- anti-Sm positive
- FGFR positive
- GPC3 positive
- HBsAg positive
- MSI positive
- MSI-H negative
- PD-1 negative
- AR positive
- ASXL1 positive
- CDK4 positive
- CLDN18.2 positive
- HBV DNA positive
- HBsAg negative
- HPV16 positive
- MSI negative
- NF2 positive
- NRAS negative
- RUNX1 positive
- STK11 positive
- TP53 negative
- p53 positive
- t(11;14) positive
- BRCA negative
- CD19 negative
- CD3 positive
- DMD positive
- FANCA positive
- MMR negative
- MSS negative
- NTRK negative
- RAD51C positive
- ZnT8 positive
- dMMR negative
- BCR-ABL positive
- CD4 positive
- EZH2 positive
- FLT3 negative
- FMR1 positive
- HR negative
- JAK2 positive
- PDGFRA positive
- RAD51D positive
- RAF positive
- RF positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- ABCA4 positive
- APC positive
- BAP1 positive
- BARD1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD4 count positive
- CD5 positive
- CD70 positive
- CDK12 positive
- DLL3 positive
- EBV positive
- EPCAM positive
- GATA2 positive
- GRN positive
- HBcAb negative
- HbSC positive
- IA-2 positive
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- TERT positive
- TROP2 positive
- del(17p) positive
- pMMR positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APOL1 positive
- ApoE ε4 positive
- B7-H3 positive
- CDK6 positive
- CEA positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- Complex karyotype positive
- DMPK positive
- DNMT3A positive
- ER or PR positive
- FANCL positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSβ0-thalassemia positive
- ICA positive
- L858R positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- PAH positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 or more Spontaneous Breathing Trials (SBTs)
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
16183 trials
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Graves Disease trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if a new drug, BHV-3000, is safe and effective in treating migraines in children and adolescents.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if lebrikizumab is effective and safe for adults with chronic sinus and nasal polyps who are already using nasal corticosteroids. The study will take around
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
Get notified when new Gastroparesis trials are postedWe'll send you an email whenever new trials are posted
SummaryThis trial seeks to evaluate if CIN-102 can reduce symptoms of diabetic gastroparesis in adults. Participants will compare effects of drug and placebo treatments over 12 weeks.
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
1
2
3
…50